Borne from Dolomite Microfluidics, with 20 years experience in particle technology, and a strong heritage of microfluidics, engineering and nanoparticle expertise, our range of platforms allow you to transfer between discovery, through development to manufacturing using the same process technology.
We have been at the forefront of this rapidly changing science, listening and adapting as our customers’ needs have evolved. We pave the way to particle perfection, helping our customers produce nanoparticles with unrivalled precision, quality, consistency and control, while reducing your development time and cost. Our product is your process.
Nanoparticles and nanoscale drug delivery systems (for materials such as small molecules, genetic material and other APIs) have become a significant part of the medical industry’s product research and development focus and the demand for nanoparticle-based medicines and therapies has exploded in recent years. The COVID-19 pandemic catapulted mRNA-based therapeutics into the forefront of life science, realizing the benefits of collaborative global efforts for unprecedented drug development.
Nanoparticles offer a range of key benefits over traditional approaches to drug delivery. They enhance bio-targeting and particle stability, surround and protect the cargo, can encapsulate both hydrophobic and hydrophilic APIs or markers, enable cargo release at an appropriate time, and only require small amounts of precious materials for vaccine development, gene therapy, and drug development applications.
There is a clear need for automated, effective and efficient production of LNPs for screening, optimization and manufacturing. We recognise that rapid product development requires acceleration and parallel task execution, and scalability and automation are key to address both requirements. Microfluidics is central to achieving scalability and quality issues that traditional methods cannot address.
Microfluidics controls particle size, achieves excellent monodispersity and encapsulation efficiency. Particle integrity is preserved and damage caused by mechanical forces is avoided. Particle Works has developed 4 core platforms to meet the various demands of the drug discovery journey, and using our reusable microfluidics chips ensures that our process technology is scalable across the whole of your drug development pipeline.
Using the same microfluidic chips and pumping technology at every stage of nanoparticle development ensures your formulations are transferrable and scalable right through from discovery, through development to scale-up and manufacturing.
We are on a journey together. From our game-changing screening platform ALiS - the first to bring automation and high-throughput screening to the marketplace; to the ANP System - a unique, comprehensive and flexible single system for both process optimisation and continuous production; to Pilot - our scale-up system; our innovative, pioneering technologies offer the complete solution for our customers’ drug development pipeline.
The Automated Library Synthesis (ALiS) System enables automation and high-throughput screening of LNP formulations and mRNA candidates in early-stage development. The platform delivers excellent monodispersity and encapsulation efficiency, enabling upto 96 experiments in under 6 hours.
The Automated Nanoparticle (ANP) System enables automation of process development and initial production of larger samples of LNPs with a select number of promising formulations, tailored to the user’s individual needs for flexible multi-sample and multi-protocol capability.
The ANP System offers the best solution for nanoparticle formulation and process optimization providing robust, reproducible results and enabling us to deliver complex projects.
We have complete faith in Particle Works' capabilities.
Using Particle Works technology to create precisely manufactured nanoparticles, coupled with their novel microfluidic technology and ability to scale up production, has been essential in Mologic’s development of ground-breaking diagnostic products.
I joined Particle Works because I believe it's going to make a huge impact on the most challenging and greatly unmet need for LNP gene formulation design, screening and manufacturing towards accelerated clinical applications.
